专利检索 ap:("CytomX Therapeutics, Inc.") AND inv:"Lori Carman" 第 1 页

1.

发明申请
ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF 有权

公开(公告)号：US20220162332A1

公开(公告)日：2022-05-26

申请号：US17471804

申请日：2021-09-10

申请人： CytomX Therapeutics, Inc.

发明人： Rachel Humphrey , Lori Carman , Matthias Will , Beiyao Zheng , Kathe Balinski

IPC分类号： C07K16/28 , A61K47/65 , A61P35/00

摘要： The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

2.

发明申请
ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：US20190016814A1

公开(公告)日：2019-01-17

申请号：US15995066

申请日：2018-05-31

申请人： CytomX Therapeutics, Inc.

发明人： Rachel Humphrey , Lori Carman , Matthias Will , Beiyao Zheng , Kathe Balinski

IPC分类号： C07K16/28 , A61P35/00 , A61K47/65

摘要： The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

3.

发明授权
Activatable anti-PDL1 antibodies, and methods of use thereof 有权

公开(公告)号：US11168144B2

公开(公告)日：2021-11-09

申请号：US15995066

申请日：2018-05-31

申请人： CytomX Therapeutics, Inc.

发明人： Rachel Humphrey , Lori Carman , Matthias Will , Beiyao Zheng , Kathe Balinski

IPC分类号： C07K16/28 , A61K47/65 , A61P35/00 , A61K39/00

摘要： The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.